For Institutions
About
Bristol Myers Squibb (BMS) has reported positive results from the Phase III SCOUT-HCM trial for Camzyos (mavacamten) in treating symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in adolescents aged 12 to under 18. The trial met its primary endpoint, showing significant reduction in Valsalva left ventricular outflow tract (LVOT) gradient at week 28 compared to placebo. Safety data remained consistent with adult profiles, and BMS plans to present comprehensive results at a medical congress. The study continues with active treatment and long-term extension phases.
Bristol Myers Squibb (BMS) CEO Christopher Boerner expressed confidence in the company's core pipeline to offset revenue losses from patent expiries of top drugs Opdivo and Eliquis by 2030. At the J.P. Morgan Healthcare conference, Boerner highlighted upcoming pivotal readouts for six assets in 2026 across various therapeutic areas, with potential for 10 new medicine launches. BMS aims to maintain focus on its core expertise rather than pursuing acquisitions, while also announcing positive trial results for Camzyos in adolescents with obstructive hypertrophic cardiomyopathy.
UBS has upgraded Altria Group, Inc. (NYSE:MO) from Neutral to Buy, raising its price target from $61 to $63. This upgrade is based on an improving industry outlook for 2026 and the belief that the decline in Altria's cigarette volume may be stabilizing. Altria is also recognized as one of the 13 Best Dividend Stocks Paying Over 6%.
Altria Group's shares rose approximately 2% to $57.06 following an upgrade from UBS, which changed its rating from "neutral" to "buy" and increased the price target to $63 from $61. UBS noted potential revenue growth and accelerated EPS growth over the next two years, suggesting that the worst of the cigarette volume decline may be over. Currently, six out of 16 brokerages rate the stock as "buy" or higher, with a median price target of $62.50.
ONEOK Inc's (NYSE:OKE) short interest has increased by 11.67%, with 19.76 million shares sold short, representing 3.54% of available shares. It would take approximately 4.95 days to cover these short positions. An increase in short interest often indicates bearish sentiment among investors. Compared to its peers, ONEOK Inc has a higher short interest percentage of 3.54%, while the average for its peer group is 3.26%.
